Join the CRM Legacy Meeting for a comprehensive examination of Cardio-Renal-Metabolic health, focusing on the Empagliflozin-Linagliptin combination. Our expert panel will delve into the latest clinical evidence, exploring the benefits and applications of this dual therapy approach. This insightful session will provide actionable strategies for optimizing CRM patient outcomes, making it an essential event for healthcare professionals seeking to enhance their CRM practice.

CRM Legacy Meeting Unlocking Cardio-Renal-Metabolic Health: A Webinar on Empagliflozin-Linagliptin Combination

Senior Consultant, Endocrinology & Diabetes, Indraprastha Apollo Hospital, New Delhi

This session explores the evolving paradigm of cardio-renal-metabolic care, highlighting how SGLT2 inhibitor and DPP-4 inhibitor combinations can improve outcomes in patients with type 2 diabetes and associated co-morbidities. It focuses on mechanisms, patient selection, real-world evidence, and practical strategies to achieve comprehensive heart, kidney, and metabolic protection in routine clinical practice.

Dr. Prof Subhash K Wangnoo

3

419

6.8k

4.7

Upcoming Sessions

Sessions Taken

228

4.6

446

4.7